Supplementary Figure S6 from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies

Supplementary Fig. S6. Phenotype of preactivated and expanded CB-NK cells upon AFM13 triggering.